Evox Therapeutics Inc

عن الشركة

Evox Therapeutics is a pioneering biotechnology company focused on developing next-generation genetic medicines for severe neurodegenerative diseases. Founded in 2016 from breakthrough science originating at the University of Oxford and Karolinska Institute, Evox is working to expand the reach of genetic medicine into the brain and address the root causes of disease. Our proprietary ExoEdit® platform combines the natural delivery capabilities of exosomes with advanced CRISPR-based genome editing technology, with the goal of developing safer, more effective, and scalable treatments for diseases affecting the central nervous system. Evox is advancing a pipeline of innovative programs, including lead programs targeting Huntington’s disease and ALS, while exploring broader opportunities across genetically driven neurological diseases. Our work brings together expertise across biotechnology, gene editing, extracellular vesicles, drug development, and translational science.